Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $15.98, but opened at $17.06. Daiichi Sankyo shares last traded at $16.98, with a volume of 16,495 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, Daiichi Sankyo currently has a consensus rating of “Hold”.

Daiichi Sankyo Stock Performance

The stock has a market cap of $31.67 billion, a price-to-earnings ratio of 18.09, a P/E/G ratio of 2.83 and a beta of -0.17. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. The company has a 50 day simple moving average of $16.28 and a 200 day simple moving average of $18.35.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, equities research analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.98 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.